Looking beyond targeting Ras directly, BRaf inhibitors developed to target the popular V600E mutant (vemurafenib, dabrafenib, etc.)have been pursued for their disruption of the MAPK-ERK pathway in cancers with BRaf-driven cancers, including BRaf mutant melanoma and NSCLC [193]. This evidence concerns the gene BRAF and cancer.